BackInDex Pharmaceuticals Holding AB (publ) Overview

InDex Pharmaceuticals Holding AB (publ) Receivables

Latest receivables for INDEX.ST: $190M.

Get informed when a big investor buys or sells

+ Follow
Receivables
$190.00M
↓ 40.63% YoYΔ $-130.00M vs prior year quarter

Peer trimmed avg / median

Loading

InDex Pharmaceuticals Holding AB (publ) Receivables History

Loading

InDex Pharmaceuticals Holding AB (publ) vs. peers: Receivables Comparison

Loading

InDex Pharmaceuticals Holding AB (publ) Receivables Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

InDex Pharmaceuticals Holding AB (publ) (INDEX.ST) FAQ

As of the most recent data (September 2026), INDEX.ST shows a receivables of $190M. That compares with $320M in the prior-year period — down 40.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, INDEX.ST's receivables is now $190M (was $320M) — a 40.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether InDex Pharmaceuticals Holding AB (publ) is outperforming or lagging.

Tracking INDEX.ST's receivables over time shows whether InDex Pharmaceuticals Holding AB (publ) is scaling, shrinking, or reshaping that part of the business. The current reading is $190M That compares with $320M in the prior-year period — down 40.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this receivables page, Stockcircle has InDex Pharmaceuticals Holding AB (publ)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect receivables (currently $190M) with ownership activity and broader fundamentals.

InDex Pharmaceuticals Holding AB (publ)'s receivables is $190M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.